Y-Biologics, a South Korean biotechnology company, and French pharmaceutical group Pierre Fabre have signed a license agreement granting Pierre Fabre rights globally exclusive to develop and commercialize a family of human antibodies generated through the Y-Biologics proprietary Y-Biologics phage display human antibody library Ymax-ABL.
These antibodies have been functionally validated by Pierre Fabre's R&D teams for their specific properties on a fundamental immuno-oncological target that acts in the tumor microenvironment. Pierre Fabre intends to select a new therapeutic candidate in immuno-oncology for further development.
This license agreement is the result of the strong and now proven complementarity between the two companies that have been collaborating since 2018. The ultimate goal pursued by Y-Biologics and Pierre Fabre is to provide patients with innovative drugs targeting refractory or recurrent cancer, taking advantage of the immune infiltrate to inhibit the growth of tumor cells.
This new milestone reached by the two companies reveals the effectiveness of the scientific means set up by Y-Biologics, associated with Pierre Fabre's extensive experience in oncology.
Young Woo Park, CEO of Y-Biologics, stated: “We are very happy to sign our first license agreement with Pierre Fabre. The collaboration between Y-Biologics and Pierre Fabre, based on mutual trust, is expected to advance the development of innovative immuno-oncological therapies targeting the tumor microenvironment.”
“Since the beginning of our partnership, the collaboration with Y-Biologics has been very efficient and fruitful. Their library has enabled us to identify a family of human antibodies against a promising target defined by our researchers at our dedicated Immunology Center. This new e an interesting license agreement will allow us to continue supporting the development of this therapy for the benefit of patients, “added Nathalie Corvaïa, Head of Immuno-Oncology Research, and Center for Immunology Pierre Fabre (CIPF).
